THE LIVE, attenuated rubella virus vaccine (official name: Rubella Virus Vaccine, Live) soon to become available appears to be a highly effective immunizing agent and the first suitable method of controlling rubella.
Rubella is generally a mild illness, but if the infection is acquired by a woman in the early months of pregnancy, it poses a direct hazard to the fetus. Preventing infection of the fetus is the principal objective of rubella control. This can best be achieved by eliminating the transmission of virus among children, who are the major source of infection for susceptible pregnant women. Furthermore, the live, attenuated rubella virus vaccine is safe and protective for children, but not for pregnant women because of an undetermined risk of the vaccine virus for the fetus.
Rubella is one of the common childhood exanthems. Most cases occur in school age children particularly during the winter and spring. By
Recommendation of the Public Health Service Advisory Committee on Immunization Practices. Am J Dis Child. 1969;118(2):397–399. doi:10.1001/archpedi.1969.02100040399039
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: